CDI-988 (Oral Pan-viral protease inhibitor)

About Cocrystal Pharma

Cocrystal Pharma is a clinical-stage biotech leveraging a proprietary structure-based drug discovery platform, underpinned by Nobel laureate Dr. Roger Kornberg's expertise, to design novel antiviral therapeutics. Its strategy focuses on targeting highly conserved viral replication enzymes to develop broad-spectrum, resistance-resistant drugs for high-need indications like influenza, coronaviruses, and norovirus. The company has achieved key milestones, including completing a Phase 2a human challenge study for its lead influenza candidate and initiating a Phase 1b study for its dual coronavirus/norovirus protease inhibitor. With a lean operational model and a pipeline spanning early discovery to Phase 2, Cocrystal aims to efficiently advance its candidates toward pivotal trials and partnerships.

About Cocrystal Pharma

Cocrystal Pharma is a clinical-stage biotech leveraging a proprietary structure-based drug discovery platform, underpinned by Nobel laureate Dr. Roger Kornberg's expertise, to design novel antiviral therapeutics. Its strategy focuses on targeting highly conserved viral replication enzymes to develop broad-spectrum, resistance-resistant drugs for high-need indications like influenza, coronaviruses, and norovirus. The company has achieved key milestones, including completing a Phase 2a human challenge study for its lead influenza candidate and initiating a Phase 1b study for its dual coronavirus/norovirus protease inhibitor. With a lean operational model and a pipeline spanning early discovery to Phase 2, Cocrystal aims to efficiently advance its candidates toward pivotal trials and partnerships.

Therapeutic Areas